THE NEW QOF CHOLESTEROL INDICATORS AND HOW LEQVIO^® (INCLISIRAN) COULD HELP YOUR PRACTICE ACHIEVE THE TARGETS^1,2

^†Based on a meta-analyses of data from randomised statin trials with 174,149 patients over an average of 4.9 years. The estimated absolute reduction in major vascular events in participants with 5-year risk of these events >10% was around 11 per 1,000 over 5 years for each 1.0 mmol/L LDL-C reduction
^‡National data covering the period up to March 2022. Data was received from 96.6% of GP practices, including approximately 18 million patients.
§At Month 17, Leqvio delivered placebo-corrected LDL-C reductions of 52%, as compared with baseline (95% CI: -55.7 to -48.8; P>0.001) in ORION-10, and of 50%, as compared with baseline (95% CI: -53.1 to -46.6; P>0.001) in ORION-11, with respective time-adjusted LDL-C reductions of 54% (95% CI: -56.2 to -51.3; P>0.001) and of 49% (95% CI: -51.6 to -46.8; P>0.001) from baseline between Months 3 and 18 relative to placebo. ORION-10 (N=1,561) and ORION-11 (N=1,617) were multicentre, double-blind, randomised, placebo-controlled 18-month clinical trials evaluating adult patients with ASCVD, and with ASCVD or risk equivalents, respectively. ⁸ ASCVD was defined as coronary heart disease, cerebrovascular disease or peripheral arterial disease¹⁰. ASCVD risk equivalents included type 2 diabetes, HeFH, or a 10-year risk of a cardiovascular event of ≥20% as assessed by the Framingham Risk Score for Cardiovascular Disease or equivalent.⁸

1. LEQVIO®. Summary of Product Characteristics. Accessed May 2023. https://www.medicines.org.uk/emc/product/12039/smpc#gref

2. NHS. Quality and Outcomes Framework Guidance for 2023/24. 2023. Accessed May 2023. https://www.england.nhs.uk/publication/quality-and-outcomes-framework-guidance-for-2023-24/

3. NHS. Changes to the GP Contract in 2023/24. Accessed May 2023. https://www.england.nhs.uk/long-read/changes-to-the-gp-contract-in-2023-24/

4. Laight D. Can LDL cholesterol ever be lowered too much? Prescriber. 2018;29(8):13-18.

5. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111-188.

6. CTT Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-590.

7. HQIP. CVDPREVENT Third Annual Audit Report. 2023. Accessed May 2023. https://www.hqip.org.uk/wp-content/uploads/2023/03/Ref-376-CVDPREVENT-Third-Annual-Audit-Report.pdf

8. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine. 2020;382(16):1507-1519.

9. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine. 2020;382(16):1520-1530.

10. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (trial protocol). New England Journal of Medicine. 2020;382(16):1507-1519.